Business
Acumen is a clinical-stage biopharmaceutical company developing sabirnetug, a disease-modifying approach aimed at soluble amyloid-beta oligomers in Alzheimer disease.
Acumen remains a pre-revenue Alzheimer's biotech with wider losses, lower equity, and a going-concern warning.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage Alzheimer disease biotechNote
- Revenue — No product revenue in local bundleNote
- Profitability — Net loss widened to $121.3MWatch
- Cash burn — Free cash flow was -$115.6MWatch
- Balance sheet — Equity -61.3% to $70.4MWatch
- Insiders — 0 buys / 40 sellsWatch
- Accounting — Going-concern language in auditor reportWatch
Leadership changes
From Acumen Pharmaceuticals, Inc.'s own filings, the day they're filed.
- James Doherty · President · appointmenteff. 2024-02-01
- Sean Stalfort · Chairman · appointment
Latest filings
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Acumen Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.